Skip to main content

Table 1 Clinical trials of therapeutic vaccines in lung cancer

From: Trends and advances in tumor immunology and lung cancer immunotherapy

Vaccine Phase Pt No. Stages Results
MAGE-A3 II 182 IB/II DFI: (HR: 0.75, 95 % CI, 0.46 to 1.23; two-sided P = .254); DFS: (HR: 0.76; 95 % CI, 0.48 to 1.21; P = .248); OS: (HR, 0.81; 95 % CI, 0.47 to 1.40; P = .454) [59].
BLP25 II 171 IIIB/IV Median OS: 17.4 months with L-BLP25/BSC vs 13.0 months with BSC alone [68].
Subset analysis (n = 65):
Median OS: 30.6 months with L-BLP25/BSC vs 13.3 months with BSC alone [69].
III 1239 III Median OS: 25.6 months with L-BLP25 vs 22.3 months with placebo [70].
Subset analysis (patients with previous chemoradiotherapy):
Median OS: 30.8 months with L-BLP25 vs 20.6 months with placebo [70].
Belagenpumatucel-L II 75 II/IV Estimated 2-years survival: 52 % with high doses vs 20 % with low doses [75].
III 532 III/IV Median OS: 20.3 months with belagenpumatucel-L vs 17.8 months with placebo [76].
Subset analysis (patients with pretreatment radiation):
Median OS: 40.1 months with belagenpumatucel-L vs 10.3 months with placebo [76].
CIMAvax EGF II 80 IIIB/IV Median survival: 11.7 months with GAR vs 3.6 months with PAR [81].
TG4010 II 148 IIIB/IV 6-months PFS: 43.2 % with TG4010/chemotherapy vs 35.1 % with chemotherapy alone [84].
  1. Abbreviations: DFI disease free interval, DFS disease-free survival, OS overall survival, HR hazard ratio, BSC best supportive care, PFS progression free survival, GAR good anti-EGF antibody response, PAR poor antibody response